Skip to main navigation
logo

Investor Relations

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Leadership
    • Committee Composition
    • Code of Business Conduct and Compliance Hotline
  • Financials & Filings
    • SEC Filings
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR

News Releases

12 03 / 2026
Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
Reports record fourth quarter  2025 total revenue of $11.3 million, representing 37% growth compared to fourth quarter 2024 Reports full year 2025 total revenue of $33.6 million, representing 20% growth compared to 2024 Amgen expands global Growth Direct system rollout with significant multi-system
12 03 / 2026
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
Companies deepen partnership to advance automated, integrated microbiology quality control LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions
10 03 / 2026
Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum
LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,
26 02 / 2026
Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,
24 02 / 2026
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,
12 02 / 2026
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,
13 01 / 2026
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period. Received record multi-system order in the fourth quarter from an existing Top 20 global biopharma customer to automate global manufacturing
07 01 / 2026
Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare Conference
LEXINGTON, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products,

Featured Pages

Stock Information
Stock Information
Governance
Governance
SEC Filings
SEC Filings
FAQs
FAQs

Investor Tools

  • RSS Feeds
  • Print Page
  • Email Alerts
  • Contact IR

© 2026 Rapid Micro Biosystems, Inc.     All rights reserved.